candesartan has been researched along with Innate Inflammatory Response in 39 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of a 6-week treatment with the AT1 receptor antagonist candesartan (16 mg/d) on endothelial function and serum inflammation markers was compared with the effect of treatment with placebo or the calcium channel antagonist felodipine (5 mg/d) in 47 hypercholesterolemic patients (low density lipoprotein cholesterol >160 mg/dL)." | 9.10 | Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. ( Böhm, M; Hilgers, S; Laufs, U; Nickenig, G; Wassmann, S, 2002) |
| " We investigated whether exaggerated BPV aggravates hypertensive cardiac remodeling and function by activating inflammation and angiotensin II-mediated mechanisms." | 7.75 | Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. ( Anegawa, T; Hirooka, Y; Ikeda, A; Imaizumi, T; Kai, H; Kajimoto, H; Kato, S; Koga, M; Kudo, H; Mifune, H; Mori, T; Takayama, N; Yasuoka, S, 2009) |
| "Pretreatment with candesartan for 10 days reduced significantly the ulcer index induced by indomethacin injection." | 5.38 | Immunomodulatory effect of candesartan on indomethacin-induced gastric ulcer in rats. ( Awad, AS; El Morsy, EM; Kamel, R, 2012) |
| "Candesartan was more effective at reducing macrophage accumulation and collagen I abundance in plaques compared with rosuvastatin." | 5.35 | The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. ( Boolell, V; Calkin, AC; Chew, C; Cooper, ME; Giunti, S; Jandeleit-Dahm, KA; Rajaram, YS; Sheehy, KJ, 2008) |
| " Beginning 8 wk after birth, SHR underwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg per d (T5), high 25 mg/kg per d (T25), or ultrahigh 75 mg/kg per d dosage (T75)." | 5.34 | Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. ( Dworkin, LD; Gong, R; Rifai, A; Tolbert, EM; Yu, C, 2007) |
| " Chronic administration of a subdepressor dose of an angiotensin II type 1 receptor blocker candesartan reduced the pressure overload-induced dihydroethidium and 4-HNE signals at day 3." | 5.33 | Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. ( Fukui, D; Imaizumi, T; Kai, H; Kudo, H; Kuwahara, F; Mori, T; Sugi, Y; Tahara, N; Takayama, N; Takemiya, K; Tokuda, K; Yasukawa, H, 2006) |
| "The effect of a 6-week treatment with the AT1 receptor antagonist candesartan (16 mg/d) on endothelial function and serum inflammation markers was compared with the effect of treatment with placebo or the calcium channel antagonist felodipine (5 mg/d) in 47 hypercholesterolemic patients (low density lipoprotein cholesterol >160 mg/dL)." | 5.10 | Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. ( Böhm, M; Hilgers, S; Laufs, U; Nickenig, G; Wassmann, S, 2002) |
| "We administered placebo or candesartan 16 mg daily during two months to 45 patients with mild-to-moderate hypertension." | 5.10 | Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. ( Ahn, JY; Ahn, TH; Choi, IS; Han, SH; Jin, DK; Kim, DS; Kim, HS; Koh, KK; Shin, EK; Shin, MS, 2003) |
| " show that candesartan (Cand) displays an antioxidant action independent of angiotensin type 1 receptor (AT1R) blockade that translates into a superior renoprotection of chronic renal inflammation." | 4.84 | Candesartan and renal protection: more than blocking angiotensin type 1 receptor? ( Macconi, D; Remuzzi, G, 2008) |
| "Candesartan protected against vascular inflammation and restored endothelial function after SES implantation." | 3.77 | Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents. ( Daida, H; Dohi, T; Iesaki, T; Kasai, T; Kubota, N; Miyauchi, K; Ogita, M; Tsuboi, S; Tsuruta, R; Yokoyama, T, 2011) |
| " We investigated whether exaggerated BPV aggravates hypertensive cardiac remodeling and function by activating inflammation and angiotensin II-mediated mechanisms." | 3.75 | Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. ( Anegawa, T; Hirooka, Y; Ikeda, A; Imaizumi, T; Kai, H; Kajimoto, H; Kato, S; Koga, M; Kudo, H; Mifune, H; Mori, T; Takayama, N; Yasuoka, S, 2009) |
| "Treatment with candesartan had no influence on serum YKL-40 levels." | 2.78 | Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. ( Arnesen, H; Seljeflot, I; Smith, P; Svendsen, JH; Tveit, A, 2013) |
| " Furthermore, because of the notorious subtarget dosing of such agents in clinical practice, we explored the influence of a modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type 1 receptor blockers, and the combination on common biologic markers of coronary atherosclerotic disease." | 2.72 | Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination. ( Cox, CD; Meyerrose, GE; Peek, MC; Seifert, CF; Simoni, JS; Tsikouris, JP, 2006) |
| "Proteinuria is common following kidney transplantation and affects more than 40% of kidney transplant patients per year." | 2.47 | Causes and consequences of proteinuria following kidney transplantation. ( G-Cosío, F; Suárez Fernández, ML, 2011) |
| " There was a marked decrease in nitric oxide (NO) bioavailability and antioxidant enzyme capacity." | 1.40 | Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. ( El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A, 2014) |
| "Candesartan treatment for 4 weeks significantly reduced these parameters." | 1.39 | Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. ( Chen, X; Endo, S; Guo, Q; Hu, C; Ito, S; Jiang, Y; Miyata, T; Mori, T; Nakayama, K; Nakayama, M; Ogawa, S; Ohsaki, Y; Yoneki, Y; Zhu, W, 2013) |
| "Treatment with candesartan alone increased cortical BZ(1) binding, and decreased γ(2) subunit mRNA expression in the cingulate cortex." | 1.38 | Angiotensin II AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress. ( Honda, M; Saavedra, JM; Sánchez-Lemus, E, 2012) |
| "Pretreatment with candesartan for 10 days reduced significantly the ulcer index induced by indomethacin injection." | 1.38 | Immunomodulatory effect of candesartan on indomethacin-induced gastric ulcer in rats. ( Awad, AS; El Morsy, EM; Kamel, R, 2012) |
| "Brain inflammation has a critical role in the pathophysiology of brain diseases of high prevalence and economic impact, such as major depression, schizophrenia, post-traumatic stress disorder, Parkinson's and Alzheimer's disease, and traumatic brain injury." | 1.37 | Angiotensin II AT1 receptor blockade ameliorates brain inflammation. ( Benicky, J; Chuang, DM; Honda, M; Leng, Y; Orecna, M; Pang, T; Saavedra, JM; Sánchez-Lemus, E; Wang, J, 2011) |
| "Candesartan was more effective at reducing macrophage accumulation and collagen I abundance in plaques compared with rosuvastatin." | 1.35 | The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. ( Boolell, V; Calkin, AC; Chew, C; Cooper, ME; Giunti, S; Jandeleit-Dahm, KA; Rajaram, YS; Sheehy, KJ, 2008) |
| " Beginning 8 wk after birth, SHR underwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg per d (T5), high 25 mg/kg per d (T25), or ultrahigh 75 mg/kg per d dosage (T75)." | 1.34 | Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. ( Dworkin, LD; Gong, R; Rifai, A; Tolbert, EM; Yu, C, 2007) |
| " Chronic administration of a subdepressor dose of an angiotensin II type 1 receptor blocker candesartan reduced the pressure overload-induced dihydroethidium and 4-HNE signals at day 3." | 1.33 | Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. ( Fukui, D; Imaizumi, T; Kai, H; Kudo, H; Kuwahara, F; Mori, T; Sugi, Y; Tahara, N; Takayama, N; Takemiya, K; Tokuda, K; Yasukawa, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (53.85) | 29.6817 |
| 2010's | 17 (43.59) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Timaru-Kast, R | 1 |
| Coronel-Castello, SP | 1 |
| Krämer, TJ | 1 |
| Hugonnet, AV | 1 |
| Schäfer, MKE | 1 |
| Sebastiani, A | 1 |
| Thal, SC | 1 |
| Horjen, AW | 1 |
| Ulimoen, SR | 1 |
| Norseth, J | 1 |
| Svendsen, JH | 2 |
| Smith, P | 3 |
| Arnesen, H | 3 |
| Seljeflot, I | 3 |
| Tveit, A | 3 |
| Ahmed, HI | 1 |
| Mohamed, EA | 1 |
| Julius, S | 1 |
| Egan, BM | 1 |
| Kaciroti, NA | 1 |
| Nesbitt, SD | 1 |
| Chen, AK | 1 |
| Dhande, I | 1 |
| Ma, W | 1 |
| Hussain, T | 1 |
| Hofni, A | 1 |
| El-Moselhy, MA | 1 |
| Taye, A | 1 |
| Khalifa, MM | 1 |
| Sherif, IO | 1 |
| Al-Mutabagani, LA | 1 |
| Alnakhli, AM | 1 |
| Sobh, MA | 1 |
| Mohammed, HE | 1 |
| Villapol, S | 1 |
| Balarezo, MG | 1 |
| Affram, K | 1 |
| Saavedra, JM | 6 |
| Symes, AJ | 1 |
| Sanchez-Lemus, E | 4 |
| Murakami, Y | 1 |
| Larrayoz-Roldan, IM | 1 |
| Moughamian, AJ | 1 |
| Pavel, J | 2 |
| Nishioku, T | 1 |
| Calkin, AC | 1 |
| Giunti, S | 1 |
| Sheehy, KJ | 1 |
| Chew, C | 1 |
| Boolell, V | 1 |
| Rajaram, YS | 1 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, KA | 1 |
| Chen, S | 1 |
| Ge, Y | 1 |
| Si, J | 1 |
| Rifai, A | 2 |
| Dworkin, LD | 2 |
| Gong, R | 2 |
| Macconi, D | 1 |
| Remuzzi, G | 1 |
| Bollmann, A | 1 |
| Husser, D | 1 |
| Stridh, M | 1 |
| Sörnmo, L | 1 |
| Olsson, SB | 1 |
| Benicky, J | 2 |
| Kudo, H | 3 |
| Kai, H | 3 |
| Kajimoto, H | 1 |
| Koga, M | 2 |
| Takayama, N | 2 |
| Mori, T | 3 |
| Ikeda, A | 1 |
| Yasuoka, S | 1 |
| Anegawa, T | 1 |
| Mifune, H | 1 |
| Kato, S | 1 |
| Hirooka, Y | 1 |
| Imaizumi, T | 3 |
| Derosa, G | 1 |
| Maffioli, P | 1 |
| Salvadeo, SA | 1 |
| Ferrari, I | 1 |
| Gravina, A | 1 |
| Mereu, R | 1 |
| Palumbo, I | 1 |
| D'Angelo, A | 1 |
| Cicero, AF | 1 |
| Honda, M | 2 |
| Pang, T | 1 |
| Orecna, M | 1 |
| Wang, J | 1 |
| Leng, Y | 1 |
| Chuang, DM | 1 |
| Dohi, T | 1 |
| Miyauchi, K | 1 |
| Iesaki, T | 1 |
| Tsuruta, R | 1 |
| Tsuboi, S | 1 |
| Ogita, M | 1 |
| Kubota, N | 1 |
| Kasai, T | 1 |
| Yokoyama, T | 1 |
| Daida, H | 1 |
| Suárez Fernández, ML | 1 |
| G-Cosío, F | 1 |
| Billings, FT | 1 |
| Balaguer, JM | 1 |
| C, Y | 1 |
| Wright, P | 1 |
| Petracek, MR | 1 |
| Byrne, JG | 1 |
| Brown, NJ | 1 |
| Pretorius, M | 1 |
| Kamel, R | 1 |
| El Morsy, EM | 1 |
| Awad, AS | 1 |
| Sakamoto, M | 1 |
| Suzuki, H | 1 |
| Hayashi, T | 1 |
| Iuchi, H | 1 |
| Isaka, T | 1 |
| Sakamoto, N | 1 |
| Kayama, Y | 1 |
| Tojo, K | 1 |
| Yoshimura, M | 1 |
| Utsunomiya, K | 1 |
| Chen, X | 1 |
| Guo, Q | 1 |
| Hu, C | 1 |
| Ohsaki, Y | 1 |
| Yoneki, Y | 1 |
| Zhu, W | 1 |
| Jiang, Y | 1 |
| Endo, S | 1 |
| Nakayama, K | 1 |
| Ogawa, S | 1 |
| Nakayama, M | 1 |
| Miyata, T | 1 |
| Ito, S | 1 |
| Wassmann, S | 1 |
| Hilgers, S | 1 |
| Laufs, U | 1 |
| Böhm, M | 1 |
| Nickenig, G | 1 |
| Yamada, T | 1 |
| Kuno, A | 1 |
| Masuda, K | 1 |
| Ogawa, K | 1 |
| Sogawa, M | 1 |
| Nakamura, S | 1 |
| Ando, T | 1 |
| Sano, H | 1 |
| Nakazawa, T | 1 |
| Ohara, H | 1 |
| Nomura, T | 1 |
| Joh, T | 1 |
| Itoh, M | 1 |
| Koh, KK | 1 |
| Ahn, JY | 1 |
| Han, SH | 1 |
| Kim, DS | 1 |
| Jin, DK | 1 |
| Kim, HS | 1 |
| Shin, MS | 1 |
| Ahn, TH | 1 |
| Choi, IS | 1 |
| Shin, EK | 1 |
| Schiffrin, EL | 1 |
| Touyz, RM | 1 |
| Dohi, Y | 1 |
| Ohashi, M | 1 |
| Sugiyama, M | 1 |
| Takase, H | 1 |
| Sato, K | 1 |
| Ueda, R | 1 |
| Tokuda, K | 2 |
| Kuwahara, F | 2 |
| Yasukawa, H | 2 |
| Tahara, N | 2 |
| Takemiya, K | 2 |
| Yamamoto, T | 1 |
| Skurk, T | 1 |
| van Harmelen, V | 1 |
| Hauner, H | 1 |
| Ando, H | 1 |
| Zhou, J | 1 |
| Macova, M | 1 |
| Imboden, H | 1 |
| Schram, MT | 1 |
| van Ittersum, FJ | 1 |
| Spoelstra-de Man, A | 1 |
| van Dijk, RA | 1 |
| Schalkwijk, CG | 1 |
| Ijzerman, RG | 1 |
| Twisk, JW | 1 |
| Stehouwer, CD | 1 |
| Tsikouris, JP | 1 |
| Cox, CD | 1 |
| Simoni, JS | 1 |
| Seifert, CF | 1 |
| Peek, MC | 1 |
| Meyerrose, GE | 1 |
| Doran, DE | 1 |
| Weiss, D | 1 |
| Zhang, Y | 1 |
| Griendling, KK | 1 |
| Taylor, WR | 1 |
| Sugi, Y | 1 |
| Fukui, D | 1 |
| Yu, C | 1 |
| Tolbert, EM | 1 |
| Dasu, MR | 1 |
| Riosvelasco, AC | 1 |
| Jialal, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Portable Measurement Methods Combined With Artificial Intelligence in Detection of Atrial Fibrillation[NCT04917653] | 100 participants (Anticipated) | Observational | 2021-06-07 | Recruiting | |||
| The RAS, Fibrinolysis and Cardiopulmonary Bypass[NCT00607672] | Phase 4 | 111 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Acute kidney injury (AKI) was defined according to Acute Kidney Injury Network (AKIN) criteria,specifically any increase in subject serum creatinine concentration of 50% or 0.3 mg/dL (26.5 umol/L) within 72 hours of surgery. (NCT00607672)
Timeframe: From the start of surgery until postoperative day 3
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 28.6 |
| Ramipril (ACEI) | 23.8 |
| Candesartan (ARB) | 36.4 |
Blood loss over 24 hours as measured by chest tube output (NCT00607672)
Timeframe: First 24 hours after arrival in the intensive care unit
| Intervention | mL (Mean) |
|---|---|
| Placebo | 437 |
| Ramipril (ACEI) | 470 |
| Candesartan (ARB) | 511 |
(NCT00607672)
Timeframe: From the start of surgery until discharge from hospital
| Intervention | days (Mean) |
|---|---|
| Placebo | 7.7 |
| Ramipril (ACEI) | 6.3 |
| Candesartan (ARB) | 8.1 |
New onset atrial fibrillation based on electrocardiogram (ECG) rhythm strips with a duration longer than 10 seconds (NCT00607672)
Timeframe: From arrival in intensive care unit until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 17.9 |
| Ramipril (ACEI) | 16.7 |
| Candesartan (ARB) | 27.3 |
The percentage of patients that were taken back to the operating room for re-exploration because of bleeding (NCT00607672)
Timeframe: From arrival in intensive care unit until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 3.6 |
| Ramipril (ACEI) | 8.3 |
| Candesartan (ARB) | 4.5 |
New onset neurological deficit with a duration of longer than 24 hours (NCT00607672)
Timeframe: From arrival in intensive care unit until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 7.1 |
| Ramipril (ACEI) | 4.2 |
| Candesartan (ARB) | 4.5 |
Percentage of patients that received blood product transfusion (NCT00607672)
Timeframe: From the start of surgery until discharge from hospital
| Intervention | percentage of patients (Number) | |||
|---|---|---|---|---|
| Packed red blood cells | Plasma | Platelets | Cryoprecipitate | |
| Candesartan (ARB) | 2.7 | 31.8 | 22.7 | 4.5 |
| Placebo | 67.9 | 60.7 | 46.4 | 7.1 |
| Ramipril (ACEI) | 62.5 | 29.2 | 29.2 | 4.2 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by the IL-10 response (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Pre CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 4.21 | 749.56 | 22.55 | 14.26 |
| Placebo | 4.45 | 461.90 | 30.70 | 16.74 |
| Ramipril (ACEI) | 5.36 | 815.74 | 26.89 | 14.59 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-6 (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Pre CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 6.44 | 144.76 | 218.16 | 243.72 |
| Placebo | 6.29 | 116.04 | 224.96 | 166.96 |
| Ramipril (ACEI) | 9.33 | 167.51 | 172.65 | 144.67 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-8 (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Pre CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 13.38 | 76.76 | 37.11 | 37.77 |
| Placebo | 16.18 | 66.44 | 46.18 | 34.39 |
| Ramipril (ACEI) | 11.86 | 80.07 | 37.39 | 28.06 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the fibrinolytic responses to CPB as measured by PAI-1 response (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| Pre CPB | 60min of CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 18.28 | 24.19 | 49.10 | 21.70 | 13.4 |
| Placebo | 15.14 | 20.43 | 39.69 | 31.83 | 21.59 |
| Ramipril (ACEI) | 16.25 | 19.41 | 41.62 | 26.27 | 17.33 |
To compare the effects of angiotensin II type I (AT1) receptor antagonism or angiotensin-converting enzyme (ACE) inhibition versus placebo on the fibrinolytic responses to cardiopulmonary bypass (CPB) as measured by t-PA antigen response (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| Pre CPB | 60min of CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 11.97 | 24.89 | 31.47 | 15.75 | 12.89 |
| Placebo | 14.36 | 27.65 | 34.56 | 20.25 | 16.56 |
| Ramipril (ACEI) | 14.05 | 36.67 | 41.11 | 17.10 | 12.49 |
(NCT00607672)
Timeframe: From the end of cardiopulmonary bypass until arrival in intensive care unit
| Intervention | percentage of patients (Number) | |||
|---|---|---|---|---|
| Dobutamine | Mlrinone | Norepinephrine | Epinephrine | |
| Candesartan (ARB) | 27.3 | 22.7 | 95.5 | 13.6 |
| Placebo | 35.7 | 25.0 | 85.7 | 7.1 |
| Ramipril (ACEI) | 29.2 | 25.0 | 79.2 | 4.3 |
3 reviews available for candesartan and Innate Inflammatory Response
| Article | Year |
|---|---|
Candesartan and renal protection: more than blocking angiotensin type 1 receptor?
Topics: Angiotensin II Type 1 Receptor Blockers; Antioxidants; Benzimidazoles; Biphenyl Compounds; Humans; I | 2008 |
Causes and consequences of proteinuria following kidney transplantation.
Topics: Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Endothelium, Vascular; Graft Rejection; | 2011 |
Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2003 |
11 trials available for candesartan and Innate Inflammatory Response
| Article | Year |
|---|---|
High-sensitivity troponin I in persistent atrial fibrillation - relation to NT-proBNP and markers of inflammation and haemostasis.
Topics: Aged; Antihypertensive Agents; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; | 2018 |
Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.
Topics: Adipokines; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atrial Fibrillation; Atrial R | 2013 |
In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; | 2014 |
Candesartan effect on inflammation in hypertension.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood | 2010 |
Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2012 |
Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Anti | 2012 |
Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biomarker | 2002 |
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
Topics: Angiotensin Receptor Antagonists; Angiotensins; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2003 |
Candesartan reduces oxidative stress and inflammation in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2003 |
Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized c
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mell | 2005 |
Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2006 |
25 other studies available for candesartan and Innate Inflammatory Response
| Article | Year |
|---|---|
AT 1 inhibition mediated neuroprotection after experimental traumatic brain injury is dependent on neutrophils in male mice.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Homeodomain Proteins; Inflammation; Male; | 2023 |
Candesartan and epigallocatechin-3-gallate ameliorate gentamicin-induced renal damage in rats through p38-MAPK and NF-κB pathways.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Caspase 3; Catechin; Drug Therapy, Combination; Gene Ex | 2019 |
Angiotensin AT2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production.
Topics: Anti-Inflammatory Agents; Benzimidazoles; Biphenyl Compounds; Cell Line; Drug Evaluation, Preclinica | 2015 |
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclooxygenase 2; Diabete | 2014 |
Renoprotective effects of angiotensin receptor blocker and stem cells in acute kidney injury: Involvement of inflammatory and apoptotic markers.
Topics: Acute Kidney Injury; Angiotensin Receptor Antagonists; Animals; Apoptosis; Benzimidazoles; Biphenyl | 2015 |
Neurorestoration after traumatic brain injury through angiotensin II receptor blockage.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzamides; Benzimidazoles; Benzoates; | 2015 |
Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II Type 1 Receptor Blockers; A | 2008 |
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Benzimidazoles; Biphenyl Compou | 2008 |
Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2008 |
Relation between atrial fibrillatory rate and markers of inflammation and haemostasis in persistent human atrial fibrillation.
Topics: Antihypertensive Agents; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; Electr | 2009 |
In vivo Angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; | 2009 |
Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Benzimidazoles; B | 2009 |
Angiotensin II AT1 receptor blockade ameliorates brain inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Benzimidazoles; Biphenyl Compoun | 2011 |
Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2011 |
Angiotensin II AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress.
Topics: Adrenocorticotropic Hormone; Angiotensin II Type 1 Receptor Blockers; Animals; Autoradiography; Benz | 2012 |
Immunomodulatory effect of candesartan on indomethacin-induced gastric ulcer in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Antioxidants; Benzimidazo | 2012 |
Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; B | 2013 |
Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats.
Topics: Actins; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2003 |
Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Co | 2004 |
Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB.
Topics: Adipocytes; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Re | 2004 |
Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Benzimidazoles; Biphenyl | 2004 |
Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Animals; Aorta; Atherosclerosis; Benzimidazoles; Biphe | 2007 |
Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2006 |
Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo.
Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Gene | 2009 |